News & Views
Licensing Agreement to Drive Multi-specific Biotherapeutics Development
Jan 17 2022
Zhejiang Doer Biologics Co, Ltd and Lonza have entered into a research license agreement for Doer Biologics to use Lonza’s XS Technologies® offering for production of its proprietary MultipleBody® and SMART-VHHBody platform technology. Doer Biologics is a clinical-stage biopharmaceutical company focused on the development of multi-domain-based, multi-specific innovative protein drugs in the fields of cancer, endocrinology, metabolic diseases, and ophthalmology.
The license secures Doer Biologics’ access to Lonza's XS® Pichia Expression System, providing for the development of scalable, robust, and reliable expression processes. This will enable Doer Biologics to develop, express, and manufacture multi-specific VHH based biotherapeutic proteins to address unmet medical needs in the field of immuno-oncology. Doer Biologics noted early success with the Lonza XS® Pichia Expression System in their lab and are pursuing further developments.
Peter Droc, Head of Licensing and Drug Product Services, Lonza, commented: “Next-generation therapies always demand a new take on expression systems. At Lonza, we have continued developing a toolbox of expression systems that help accommodate industry trends, eliminate production bottlenecks, align downstream processing and drive breakthroughs in the clinic. Doer Biologics has innovative R&D pipelines for VHH antibodies and we believe this agreement will further accelerate their candidates from pre-clinical study to commercial manufacturing.”
Dr Yanshan Huang, founder and CEO, Zhejiang Doer Biologics Co Ltd, added: “Multi-specific biologics often show stronger potency, extended half-life, improved therapeutic window, and higher developability compared to single-target antibodies. However, designing and developing new multi-specific antibodies represents a central challenge for the realisation of new immunotherapies. Access to Lonza’s proprietary expression technology will enable us to progress our proprietary MultipleBody® and SMART-VHHBody platform by providing high-yielding processes for our candidates. We believe that we can develop high-quality VHH based multi-specific biotherapeutics in a faster and lower-cost fashion with Lonza’s XS® Pichia Expression System.”
More information online
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan